DUBLIN--(BUSINESS WIRE)--The "Hypercholesterolemia
- Pipeline Review, H2 2017" report has been added to Research
and Markets' offering.
Hypercholesterolemia -
Pipeline Review, H2 2017, provides comprehensive information on the
therapeutics under development for Hypercholesterolemia (Metabolic
Disorders), complete with analysis by stage of development, drug target,
mechanism of action (MoA), route of administration (RoA) and molecule
type. The guide covers the descriptive pharmacological action of the
therapeutics, its complete research and development history and latest
news and press releases.
The Hypercholesterolemia (Metabolic
Disorders) pipeline guide also reviews of key players involved in
therapeutic development for Hypercholesterolemia and features dormant
and discontinued projects. The guide covers therapeutics under
Development by Companies /Universities /Institutes, the molecules
developed by Companies in Pre-Registration, Phase III, Phase II, Phase
I, Phase 0, Preclinical, Discovery and Unknown stages are 1, 9, 13, 3,
1, 20, 9 and 2 respectively. Similarly, the Universities portfolio in
Preclinical and Discovery stages comprises 7 and 2 molecules,
respectively.
Hypercholesterolemia (Metabolic Disorders)
pipeline guide helps in identifying and tracking emerging players in the
market and their portfolios, enhances decision making capabilities and
helps to create effective counter strategies to gain competitive
advantage.
Key Topics Covered:
- Introduction
- Hypercholesterolemia - Overview
- Hypercholesterolemia - Therapeutics Development
- Hypercholesterolemia - Therapeutics Assessment
- Hypercholesterolemia - Companies Involved in Therapeutics Development
- Hypercholesterolemia - Drug Profiles
- Hypercholesterolemia - Dormant Projects
- Hypercholesterolemia - Discontinued Products
- Hypercholesterolemia - Product Development Milestones
- Appendix
Companies Mentioned
- AFFiRiS AG
- Akcea Therapeutics Inc
- ARMO Biosciences Inc
- AstraZeneca Plc
- BioLingus AG
- Catabasis Pharmaceuticals Inc
- Chong Kun Dang Pharmaceutical Corp
- CymaBay Therapeutics Inc
- Daewon Pharm Co Ltd
- Daewoong Co Ltd
- Dicerna Pharmaceuticals Inc
- Dybly AG
- Esperion Therapeutics Inc
- Gemphire Therapeutics Inc
- Golden Biotechnology Corp
- Hanmi Pharmaceuticals Co Ltd
- Immune Response BioPharma Inc
- Kadmon Corp LLC
- Kyorin Pharmaceutical Co Ltd
- Leading BioSciences Inc
- LipimetiX Development Inc
- Lotus Pharmaceutical Co Ltd
- Madrigal Pharmaceuticals Inc.
- Medlab Clinical Ltd
- Nanoform Cardiovascular Therapeutics Ltd
- Noxopharm Ltd
- Pfizer Inc
- Progenra Inc
- Regeneron Pharmaceuticals Inc
- RegenxBio Inc
- Serometrix LLC
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
- The Medicines Company
- Viking Therapeutics Inc
For more information about this report visit https://www.researchandmarkets.com/research/r2zbhh/hypercholesterolem
